Vikram Purohit
Stock Analyst at Morgan Stanley
(0.76)
# 3,652
Out of 4,829 analysts
174
Total ratings
25%
Success rate
-14.68%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $151.46 | +65.06% | 19 | May 5, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Equal-Weight | $10 → $8 | $4.33 | +84.76% | 2 | Apr 10, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $58.98 | +10.21% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $107.76 | +76.32% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $9.06 | +286.31% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.20 | +114.29% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $19.36 | +60.12% | 2 | Sep 11, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $13 → $6 | $2.36 | +154.78% | 7 | Aug 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $59 → $64 | $65.87 | -2.84% | 6 | Aug 7, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.75 | +154.55% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $6.68 | +139.52% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.79 | +691.56% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $6.57 | +234.86% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $13.53 | -26.09% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $1.24 | +383.87% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $7.52 | +458.51% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $1.30 | +1,630.77% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $30.07 | +36.35% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $13.23 | +202.34% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $0.72 | +1,713.87% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $23.91 | +58.93% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.98 | +66.94% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $8.98 | +11.36% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $29.34 | -76.14% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.27 | +1,632.28% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.83 | +103.46% | 2 | Aug 5, 2020 |
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $151.46
Upside: +65.06%
Recursion Pharmaceuticals
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $4.33
Upside: +84.76%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $58.98
Upside: +10.21%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $107.76
Upside: +76.32%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $9.06
Upside: +286.31%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.20
Upside: +114.29%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $19.36
Upside: +60.12%
Acelyrin
Aug 19, 2024
Maintains: Equal-Weight
Price Target: $13 → $6
Current: $2.36
Upside: +154.78%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $59 → $64
Current: $65.87
Upside: -2.84%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.75
Upside: +154.55%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $6.68
Upside: +139.52%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $3.79
Upside: +691.56%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $6.57
Upside: +234.86%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $13.53
Upside: -26.09%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $1.24
Upside: +383.87%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $7.52
Upside: +458.51%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $1.30
Upside: +1,630.77%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $30.07
Upside: +36.35%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $13.23
Upside: +202.34%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $0.72
Upside: +1,713.87%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $23.91
Upside: +58.93%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.98
Upside: +66.94%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $8.98
Upside: +11.36%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $29.34
Upside: -76.14%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.27
Upside: +1,632.28%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.83
Upside: +103.46%